Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases

CONCLUSIONSThe recommended phase 2 dose of everolimus is 10 mg daily in combination with pasireotide and SIRT. The regimen is well tolerated. Preliminary activity appears promising. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - February 16, 2018 Category: Cancer & Oncology Authors: Hyun S. Kim, Walid L. Shaib, Chao Zhang, Ganji Purnachandra Nagaraju, Christina Wu, Olatunji B. Alese, Zhengjia Chen, Edith Brutcher, Meredith Renfroe, Bassel F. El ‐Rayes Tags: Original Article Source Type: research